Kymera Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Kymera Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • Kymera Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$72.1M, a 25.4% decline year-over-year.
  • Kymera Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$200M, a 8.3% decline year-over-year.
  • Kymera Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$166M, a 2.65% decline from 2022.
  • Kymera Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$161M, a 60.4% decline from 2021.
  • Kymera Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$101M, a 117% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$166M -$4.27M -2.65% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-22
2022 -$161M -$60.7M -60.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-22
2021 -$101M -$54.2M -117% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-22
2020 -$46.3M -$4.1M -9.71% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-23
2019 -$42.2M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.